Print Save or Share

LDMP Approval Status beta

  • FDA approved: No
  • Brand name: LDMP
  • Generic name: paroxetine mesylate
  • Company: Noven Pharmaceuticals, Inc.
  • Treatment for: Postmenopausal Symptoms

LDMP (paroxetine mesylate) is a low-dose non-hormonal therapy in development for the treatment of vasomotor symptoms associated with menopause.

FDA Approval Status for LDMP

DateArticle
Mar  6, 2013Noven Announces FDA Advisory Committee Vote on Investigational Low-Dose Mesylate Salt of Paroxetine (LDMP) for Vasomotor Symptoms Associated with Menopause
Nov 14, 2012FDA Accepts Noven's NDA For An Investigational Nonhormonal Therapy For Menopausal Vasomotor Symptoms
Aug 29, 2012Noven Submits New Drug Application for Investigational Non-Hormonal Therapy for Menopausal Vasomotor Symptoms

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Advertisement
Close

Recommended

(web1)